Evidence map›Paper›PMID 33872342›Full record

SynthesisPloS one2021

Prognostic value of the postoperative neutrophil-lymphocyte ratio in solid tumors: A meta-analysis.

Meilong Wu, Shizhong Yang, Xiaobin Feng, Chengquan Li, Fei Yu, Jiahong Dong

RetractedAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Immunosurveillance in clinical cancer management.CA: a cancer journal for clinicians
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Meilong WuSchool of Clinical Medicine, Tsinghua University, Haidian District, Beijing, China.ORCID 0000-0002-1336-2559
Shizhong YangSchool of Clinical Medicine, Tsinghua University, Haidian District, Beijing, China.
Xiaobin FengSchool of Clinical Medicine, Tsinghua University, Haidian District, Beijing, China.
Chengquan LiSchool of Clinical Medicine, Tsinghua University, Haidian District, Beijing, China.
Fei YuSchool of Clinical Medicine, Tsinghua University, Haidian District, Beijing, China.
Jiahong DongSchool of Clinical Medicine, Tsinghua University, Haidian District, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeNumerous studies have demonstrated that a variety of systemic inflammatory markers were associated with the survival of different tumors. However, the association between elevated postoperative neutrophil-lymphocyte ratio (postNLR) and long-term outcomes, including overall survival (OS), disease-free survival (DFS), in patients with solid tumors remains controversial. A systematic review was conducted to explore the association between the postNLR and long-term outcomes in solid tumors. MATERIALS AND

methodsRelevant literature was identified using PubMed, Embase, Web of Science, and the Cochrane Library from the initiation of the databases to October 2020. Data were extracted from included studies reporting hazard ratio (HR) and 95% confidence intervals (CI), and were pooled using generic inverse-variance and random-effects modeling. 25 studies reporting on7539 patients were included in the analysis.

resultsElevated postNLR was associated with poor OS (HR 1.87, 95% CI = 1.53-2.28; P < 0.00001), and worse DFS (HR 1.69, 95% CI = 1.28-2.22; P = 0.0002). Subgroup analyses showed that the trend of the pooled HR for most of the subgroups was not changed, and the heterogeneity of the same tumor type was not obvious. However, there was no correlation between high postNLR obtained within 7days and poor DFS (n = 3, HR 1.25, 95CI% = 0.54-2.88; P = 0.60).

conclusionsElevated postNLR might be a readily available and inexpensive biomarker for long-term outcomes in solid tumors. Multicenter and prospective studies are needed to explore the impact of the postNLR on the prognosis of solid tumors.

Indexed as

BiomarkersDisease-Free SurvivalHumansLymphocytesNeoplasmsNeutrophilsPostoperative PeriodPrognosisProgression-Free SurvivalProportional Hazards ModelsSurvival AnalysisTreatment OutcomeBiomarkers

Identifiers

PMID33872342
PMCPMC8055017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.